Anti-Rheumatic Drugs - Kyrgyzstan

Kyrgyzstan

In Kyrgyzstan, the revenue in the Anti-Rheumatic Drugs market is forecasted to reach US$1.32m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.15%, leading to a market volume of US$1.33m by 2029.
When compared to other countries worldwide, United States is projected to generate the highest revenue, amounting to US$34,700.00m in 2024.
The demand for anti-rheumatic drugs in Kyrgyzstan is steadily increasing due to the rising prevalence of rheumatic diseases in the country.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Kyrgyzstan has been on the rise in recent years, driven by various factors.

Customer preferences: Kyrgyzstan has a high prevalence of rheumatoid arthritis, which is a major driver of the demand for Anti-Rheumatic Drugs. Patients prefer to use drugs that are affordable and effective in reducing pain and inflammation associated with the disease. There is also a growing preference for biologic drugs, which offer better outcomes than traditional disease-modifying anti-rheumatic drugs (DMARDs).

Trends in the market: The Anti-Rheumatic Drugs market in Kyrgyzstan is witnessing a shift towards biologic drugs, which are more expensive than traditional DMARDs but offer better outcomes. This trend is driven by the increasing availability of biologic drugs in the market and the growing awareness among patients and healthcare professionals about their benefits. The market is also witnessing an increase in the use of biosimilars, which are cheaper versions of biologic drugs.

Local special circumstances: Kyrgyzstan has a relatively underdeveloped healthcare system, which limits access to healthcare services and drugs, particularly in rural areas. This has led to a significant unmet need for Anti-Rheumatic Drugs in the country. Moreover, the country has a large population of low-income earners who cannot afford expensive drugs, which limits the uptake of biologic drugs in the market.

Underlying macroeconomic factors: Kyrgyzstan is a low-income country with a small economy, which limits the government's ability to invest in healthcare infrastructure and services. This has led to a significant shortage of healthcare professionals and facilities in the country, which limits access to healthcare services and drugs. Furthermore, the country has a high burden of communicable diseases, which diverts resources away from non-communicable diseases such as rheumatoid arthritis.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.